Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD4 | P21917 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CD74 | P04233 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1882333 | 0.98 | NOTUM (0.66) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL12601113 | 0.85 | NOTUM (0.64) | NOTUML3MBTL1MAOADRD2DRD4 | |
| Bromide SCHEMBL1894577 | 0.84 | NOTUM (0.62) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL15729971 | 0.83 | MIF (0.64) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL20468184 | 0.83 | NOTUM (0.72) | NOTUML3MBTL1MIFP2RX7POLB | |
| SCHEMBL3406910 | 0.82 | NOTUM (0.48) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL16271168 | 0.81 | NOTUM (0.64) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL22111817 | 0.81 | MIF (0.69) | NOTUML3MBTL1CD74MIFP2RX7 | |
| SCHEMBL19220666 | 0.81 | KDM4E (0.70) | NOTUML3MBTL1NPC1P2RX7 | |
| SCHEMBL12224095 | 0.81 | RXRA (0.54) | NOTUMMIFP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023096928-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-9981950-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2303270-B1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| CN-104402834-B | 1,4-disubstituted-1,2,3-triazole compound preparation method | 河南师范大学 | 2017-02-22 | — | — | CN | disclosed |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-09-22 | — | — | US | disclosed |
| US-9328071-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2016-05-03 | — | — | US | disclosed |
| CN-104402834-A | 1,4-disubstituted-1,2,3-triazole compound preparation method | UNIV HENAN NORMAL | 2015-03-11 | — | — | CN | disclosed |
| WO-2015022335-A1 | VANCOMYCIN ANALOGS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-02-19 | — | — | WO | disclosed |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-16 | — | — | US | disclosed |
| US-8802720-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130225605-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-08-29 | — | — | US | disclosed |
| US-8445530-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| EP-2201006-A1 | (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.a. (IT) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009050258-A1 | (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | NOTUM 3259/4885L3MBTL1 1640/4885MAOA 1693/4885 |
| US-20130225605-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | NOTUM 3259/4885L3MBTL1 1640/4885MAOA 1693/4885 |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | GRIN2B, GRIN1, GRIN3A | NOTUM 4536/4885L3MBTL1 4816/4885MAOA 520/4885 |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | NOTUM 3259/4885L3MBTL1 1640/4885MAOA 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.